Insulin Glargine – BiotechReality – Information Intelligence System for Biopharma

Eli Lilly and Company has reported positive results from several Phase 3 clinical trials to assess its new once-weekly basal insulin, efsitora alfa. The trials, which are part of the QWINT program (QWINT-1, QWINT-3, and QWINT-4), explored the safety and efficacy of efsitora alfa in adult patients with type 2 diabetes. The results consistently demonstrated that efsitora alfa achieved a non-inferior reduction in A1C levels compared to daily basal insulin regimens.In the QWINT-1 study, efsitora alfa led to a significant A1C reduction of 1.31%, closely matching the 1.27% reduction observed with insulin glargine. The QWINT-3 trial again supported these results, with efsitora alfa resulting in an A1C reduction of 0.86%, which was similar to the 0.75% reduction with insulin degludec. Last, in the QWINT-4 trial, efsitora alfa resulted in a reduction of 1.07% for A1C, equal to the reduction that occurred with insulin glargine.These strong results suggest that efsitora alfa may provide an easy and effective option for type 2 diabetes patients, with the potential for increased treatment adherence as a result of its once-weekly dosing regimen. Eli Lilly has said that it will submit efsitora alfa for the treatment of adults with type 2 diabetes to worldwide regulatory authorities by the end of this year. This would potentially introduce a major new choice in diabetes treatment, providing a less frequent injection regimen for patients who need basal insulin. Source: Eli Lilly and Company Last Modified:

Tag: Insulin Glargine

Eli Lilly’s Once-Weekly Insulin Efsitora Alfa Shows Promising Results in Phase 3 Trials

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment